

## **CS Pharmaceuticals launches speciality pharmaceuticals business focused on China**

London, England, June 1, 2021, CS Pharmaceuticals Ltd. (CSP), a British speciality pharmaceutical company focused on first- and best-in-class speciality therapeutics and treatments for rare diseases in China, is pleased to announce completion of seed financing and establishment of a China subsidiary.

“We are thrilled to have completed our first seed-financing and established a subsidiary in China. CSP is a British multinational company focused on licensing Chinese commercialisation rights to Western rare disease and ophthalmology medicines. The company, with its headquarters in London and offices in Beijing, offers dedicated regulatory, market access, medical and commercial expertise, in addition to international-standard compliance and legal capabilities. The team has an impressive track record of success in China, providing partners with significant experience in this fast-growing market. With its dedicated commercialisation platform, our goal is to become the ‘go-to’ trusted licensing partner in China, with a portfolio of innovative rare disease and speciality assets while making business easier for companies wishing to develop and commercialise their products in China” said Darren Mercer, CEO of CSP.

### **Investor syndicate**

The CSP team is backed by several high-profile serial biotech entrepreneurs who have personally experienced the problems that CSP is seeking to address. Their knowledge, experience and network within the relevant market, will provide significant insights and business connections to allow CSP to introduce innovations and standards of care from the Western world to patients in China. “I am delighted to see CSP complete its seed funding round and to have such a high calibre set of Investors supporting the business” said David Wilson, Chairman and founding partner of WG partners who led the funding round.

### **About CS Pharmaceuticals**

CS Pharmaceuticals (CSP) is a British multinational pharmaceutical company focused on licensing Chinese commercialisation rights to Western rare disease and speciality medicines. The company, with its headquarters in London and offices in Beijing, offers dedicated regulatory, market access, medical and commercial expertise, in addition to international-standard compliance and legal capabilities. The team has an impressive track record of success in China, providing partners with significant experience in this fast-growing market. With its dedicated commercialisation platform, CSP is rapidly becoming a ‘go-to’ trusted licensing partner, expanding its portfolio of innovative rare disease and ophthalmology assets while making business easier for companies wishing to develop and commercialise their products in China.

[www.cspharmaceuticals.com](http://www.cspharmaceuticals.com)

### **Contacts**

CS Pharmaceuticals  
Darren Mercer, Chief Executive Officer

Tel: +44 (0) 2037 534691